Lessons learnt from pandemic A(H1N1) 2009 influenza vaccination. Highlights of a European workshop in Brussels (22 March 2010) |
| |
| Authors: | Hanquet Germaine Van Damme Pierre Brasseur Daniel De Cuyper Xavier Gregor Simon Holmberg Martin Martin Rebecca Molnár Zsuzsanna Pompa Maria Grazia Snacken René van der Sande Marianne Van Ranst Marc Wirtz Angela Neels Pieter |
| |
| Affiliation: | Consultant epidemiologist (independent) and Health Care Knowledge Centre, Brussels, Belgium; Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium; Federal Agency for Medicinal and Health Products, Brussels, Belgium; Federal Agency for Medicinal and Health Products, Brussels, Belgium; Medicines and Healthcare Products Regulatory Agency, United Kingdom; The National Board of Health and Welfare, Stockholm, Sweden; WHO Regional Office for Europe, Copenhagen, Denmark; National Center for Epidemiology, Budapest, Hungary; Ministry of Health - Communicable Diseases and International Prophylaxis Unit, Italy; European Centre for Disease Prevention and Control, Stockholm, Sweden;a RIVM - Centre Infectious Disease Control, Bilthoven, The Netherlands
b Utrecht University Medical Center, Utrecht, The Netherlands; University of Leuven, Leuven, Belgium; Hessisches Ministerium für Arbeit, Familie und Gesundheit, Hessen, Germany; Federal Agency for Medicinal and Health Products, Victor Hortaplein 40, bus 40, 1060 Brussels, Belgium |
| |
| Abstract: | This European workshop identified a number of lessons learnt in the field of vaccine licensure, prioritisation of target groups, communication on pandemic vaccines, implementation of vaccination and safety monitoring. The mild severity of the pandemic A(H1N1) 2009 influenza virus influenced the perception of pandemic vaccines, as previous pandemic preparedness had anticipated a more virulent virus. This vaccination experience provides an important opportunity for research on the long-term immunogenicity and safety of pandemic vaccines in pregnant women and children, as well as on the long-term safety of adjuvants. Preparedness for future pandemics could involve improved decision-making on target groups and increased communication on vaccine safety. |
| |
| Keywords: | Vaccines Pandemic influenza Public health |
| 本文献已被 ScienceDirect PubMed 等数据库收录！ |
|
